Foundayo (Orforglipron) Side Effects by Dose and How Long They Last

The most common Foundayo (orforglipron) side effects are nausea, constipation, diarrhea and vomiting, and nausea affected 26% of adults on 5.5 mg and 35% on 17.2 mg, against 10% on placebo (US label, section 6.1). The share of people on the drug with nausea, vomiting or diarrhea peaked around week 12 of the trials, then declined (FDA review, Figure 28). Severe stomach pain that will not go away means stopping the tablet and calling your healthcare provider right away (Medication Guide).

Key facts

• Of people with stomach side effects on Foundayo, 60% had mild, 36% moderate and 4% severe ones (US label, section 6.1).
• Side effects made 8% stop Foundayo versus 3% on placebo, with stomach symptoms accounting for stops in 5% of Foundayo users (US label, section 6.1).
• First bouts of nausea, vomiting or diarrhea were most likely in the first 4 weeks, and at any one time about 14 to 20% of people on orforglipron had them (FDA review, section 8.2.5.1).
• ATTAIN-1’s 6 mg, 12 mg and 36 mg capsules equal the 5.5 mg, 9 mg and 17.2 mg tablets, respectively (UK SmPC, section 5.1).

What are the most common Foundayo side effects?

Nausea, constipation, diarrhea and vomiting lead the list, followed by indigestion and stomach pain (US label, section 6.1). The US label pools two placebo-controlled trials in which 3,155 adults received investigational orforglipron daily for up to 72 weeks, with results presented as equivalent tablet doses (US label, sections 6.1 and 14).

The table shows reactions reported in at least 5% of a Foundayo group and more often than with placebo, by assigned tablet dose (US label, section 6.1, Table 1).

Each figure covers a group’s whole trial, the lower starting steps included (US label, section 14).

Set against placebo, that is about 16 extra people per 100 with nausea on 5.5 mg and 25 extra per 100 on 17.2 mg, and 9 and 20 extra per 100 with vomiting (US label, section 6.1).

The UK SmPC rates nausea, constipation, diarrhea, vomiting, indigestion and stomach pain very common, meaning 1 in 10 people or more, and every other row of the table common, at least 1 in 100 (UK SmPC, section 4.8).

Do Foundayo side effects get worse at higher doses?

Foundayo nausea rose from 26% on 5.5 mg to 35% on 17.2 mg and vomiting from 13 to 24%, but constipation peaked at 27% on 9 mg (US label, section 6.1).

The Foundayo label gives no separate side-effect rates for the 0.8 mg or 2.5 mg starting steps (US label, section 14).

Altered skin sensation was reported in no one assigned 5.5 mg, in 0.3% on 9 mg and in 1% on 17.2 mg, versus 0.1% on placebo (US label, section 6.1).

News reports of ATTAIN-1 quote capsule doses, which are not the strengths on your box. The 1 mg capsule equals the 0.8 mg tablet, 3 mg equals 2.5 mg, 6 mg equals 5.5 mg, 12 mg equals 9 mg, 24 mg equals 14.5 mg and 36 mg equals 17.2 mg (UK SmPC, section 5.1). The two forms are not interchangeable milligram for milligram (UK SmPC, section 5.1).

How long do Foundayo side effects last?

In the FDA’s review of the trials, the share of people on orforglipron with nausea, vomiting or diarrhea peaked around week 12 and then declined (FDA review, Figure 28). First bouts were most likely in the first 4 weeks (FDA review, Figure 26).

At any trial interval, approximately 14 to 20% of people on orforglipron had nausea, vomiting or diarrhea (FDA review, Figure 28). Across the trials, any stomach side effect affected 60% on 5.5 mg, 68% on 9 mg and 69% on 17.2 mg, versus 37% on placebo (US label, section 6.1). So at any given point most people on the tablet had none of those three symptoms, even though most had some stomach side effect during the trials.

"The incidence of nausea, vomiting, and diarrhea was higher during the FOUNDAYO dosage escalation period and decreased over time." (US label, section 6.1)

Your own climb lasts at least 60 days to 5.5 mg and at least 150 days to 17.2 mg, since each step lasts at least 30 days (US label, section 2.1).

Foundayo reaches steady state after approximately 1 week of daily dosing, with peak levels 4 to 8 hours after each tablet (US label, section 12.3). A weekly Wegovy injection reaches peak medication levels after 1 to 3 days (Wegovy label, section 12.3). The tablet also slows stomach emptying most after the first dose, with that effect diminishing over time (US label, section 12.2).

Foundayo’s elimination half-life is approximately 29 to 49 hours (US label, section 12.3); use the Foundayo dosage schedule for guidance about time in your system after stopping.

How many people stop Foundayo because of side effects?

Across the pooled trials, 8% stopped Foundayo permanently because of side effects versus 3% on placebo (US label, section 6.1). Stomach side effects caused most of these stops, 5% of everyone on Foundayo (US label, section 6.1).

The table gives stop rates by tablet dose (US label, section 6.1), with the matching trial capsule (UK SmPC, section 5.1).

ATTAIN-1 alone reported side-effect stops in 5.3 to 10.3% of participants receiving the drug versus 2.7% on placebo (ATTAIN-1).

The label permits staying on Foundayo 5.5 mg, with further increases "based on treatment response and tolerability" (US label, section 2.1). Trials allowed dose reductions or pauses for tolerability; with that flexibility, over 93% reached their target dose (FDA review, section 8.2.5.1).

The trade-off in ATTAIN-1 was mean weight loss at 72 weeks of 7.5%, 8.4% and 11.2% on the capsules that match the 5.5 mg, 9 mg and 17.2 mg tablets, against 2.1% on placebo (ATTAIN-1).

In the FDA review, 2.5% of stomach side-effect events, counted as events rather than people, were severe and 0.4% serious (FDA review, section 8.2.5.1).

After 7 or more missed doses in a row, the label restarts the climb at a lower dose to limit stomach side effects (US label, section 2.3); plan that restart with your prescriber using the Foundayo missed-dose rules.

Which Foundayo side effects are serious?

Foundayo’s serious risks include pancreatitis, severe stomach reactions and kidney injury associated with dehydration (US label, sections 5 and 6.1). Confirmed acute pancreatitis affected six people on Foundayo, 0.14 per 100 years of exposure, against 0.04 on placebo (US label, section 6.1).

Act right away on these symptoms.

• Stop Foundayo and call your healthcare provider right away for severe stomach pain that will not go away, with or without nausea or vomiting; the pain may reach your back (Medication Guide).
• Stop the tablet and get immediate help for facial, lip, tongue or throat swelling, or trouble breathing or swallowing (Medication Guide).
• Report upper stomach pain, fever, yellow skin or eyes, or clay-colored stools right away (Medication Guide).
• Tell your healthcare provider right away if nausea, vomiting or diarrhea persists (Medication Guide).

Severe stomach reactions occurred in approximately 3% on Foundayo versus 1% on placebo, and the tablet is not recommended with severe gastroparesis (US label, section 5.3).

Acute kidney injury occurred in 0.2% on Foundayo versus 0.05% on placebo; most reported cases followed digestive symptoms causing dehydration (US label, sections 5.4 and 6.1).

Gallstones occurred in 1% versus 0.7% on placebo, and acute gallbladder inflammation in 0.4% versus 0.3% (US label, section 6.1).

Allergic reactions, including anaphylaxis, occurred in 0.5% on Foundayo versus 0.3% on placebo (US label, section 6.1).

Before anesthesia or deep sedation, tell every provider you take Foundayo because delayed stomach emptying can increase the chance of food entering your lungs (US label, section 5.9).

Does Foundayo cause fatigue, hair loss or a faster heart rate?

Foundayo can cause all three, and fatigue was reported in 6% on 5.5 mg, 7% on 9 mg and 9% on 17.2 mg against 4% on placebo (US label, section 6.1). Fatigue is a single row in the label’s Table 1, with no separate row for extreme fatigue (US label, section 6.1, Table 1).

Headache affected 8 to 9% against 7% on placebo, and dizziness affected 4% versus 3% (US label, section 6.1).

Hair loss was linked with weight reduction and affected 7% of women and 0.9% of men on Foundayo, against 3% and 0.7% on placebo (US label, section 6.1). Hair-loss reports separated from placebo around week 16 and rose until approximately week 48, when they began to plateau (FDA review, Figure 30). For care steps, use the guidance on hair loss on GLP‑1 drugs.

Fast heart rate was reported in 3% versus 0.9% on placebo, with average heart rate increasing by 4 to 5 beats per minute versus 0.5 (US label, section 6.1). Low blood pressure occurred in 2% versus 0.5%, and affected 4% taking blood pressure medicines versus 1% not taking them (US label, section 6.1).

Is Foundayo easier on the stomach than the Wegovy pill?

The labels cannot settle it, because rates from one drug’s trials "cannot be directly compared to rates in the clinical trials of another drug" (US label, section 6.1). Any stomach side effect affected 60 to 69% on Foundayo against 37% on placebo (US label, section 6.1), and 74.0% on oral semaglutide 25 mg against 42.2% on placebo in OASIS 4. Severe stomach side effects affected about 3% on Foundayo and 2% on Wegovy tablets, against 1% and 0% on placebo (US label, section 5.3; Wegovy label, section 6.1).

Stomach side effects made 3 to 6% stop Foundayo and 3.4% stop Wegovy 25 mg tablets, against 0.7% and 2% on placebo (US label, section 6.1; Wegovy label, section 6.1). Altered skin sensation affected 1% on Foundayo 17.2 mg and 5% on Wegovy tablets (US label, section 6.1; Wegovy label, section 6.1). The Wegovy pill’s own pattern is in the Wegovy side-effect timeline.

What helps Foundayo side effects?

Following Foundayo’s starting dose and gradual escalation reduces the risk of gastrointestinal reactions (US label, section 2.1). In earlier orforglipron studies, steps faster than every 4 weeks above 3 mg were "not optimal due to the tolerability issue" (FDA review, dose selection).

From 5.5 mg up, the label lets you stay on a dose you tolerate instead of stepping up (US label, section 2.1).

What helps the step-up decision is a record of how each symptom moved at each dose, to show the prescriber who decides whether you increase. Pensday includes Foundayo’s strengths, daily dose logging and reminders, plus severity ratings for nausea, constipation, diarrhea, heartburn, fatigue, headache and hair loss. Its symptom patterns screen places those ratings beside your estimated medication level over a week, a month or longer. All of it is in the free tier.

Drink fluids to lower the chance of dehydration from vomiting or diarrhea, as the Medication Guide and UK SmPC advise, and use the GLP‑1 water intake calculator to set a daily target.

For meal choices during nausea, use what to eat with GLP‑1 nausea. For constipation, the steps in Mounjaro constipation relief apply to any GLP‑1.

Foundayo can be taken with or without food, swallowed whole, one tablet a day (US label, section 2.1).